Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature

Angèle Lallement; Anouck Lamoureux; Michael Hummelsberger; Alexandre Maria; Lucy Meunier

doi:10.1016/j.clinre.2023.102192

Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature

Clin Res Hepatol Gastroenterol. 2023 Oct;47(8):102192. doi: 10.1016/j.clinre.2023.102192. Epub 2023 Aug 9.

Authors

Angèle Lallement¹, Anouck Lamoureux¹, Michael Hummelsberger², Alexandre Maria³, Lucy Meunier⁴

Affiliations

¹ Département de Dermatologie, CHU Saint-Eloi, Université de Montpellier, Montpellier, France.
² Service d'oncologie médicale, Clinique St Privat, France.
³ Département de Médecine Interne & Immuno-Oncologie (MedI²O), CHU Saint Eloi, Université de Montpellier, Montpellier, France.
⁴ Département d'Hépato gastro entérologie et Transplantation, CHU Saint Eloi, Université de Montpellier, Montpellier, France. Electronic address: Lucy.meunier@chu-montpellier.fr.

PMID: 37567465
DOI: 10.1016/j.clinre.2023.102192

Abstract

We report the case of a 63-year-old patient with recurrence of acral malignant melanoma after adjuvant immune checkpoint inhibitors (ICI) treatment by PEMBROLIZUMAB complicated with immune-related grade II hepatitis. Rechallenge by combination immune checkpoint (NIVOLUMAB + IPILIMUMAB) led to a relapse of the immune-related hepatitis up to a grade 3. Combination ICI therapy was carried on after introduction of corticosteroid therapy. Here, we present the outcomes of this immune-related adverse event (irAE) and a review of literature on the subject.

Keywords: Cancer; Hepatitis; Immune checkpoint inhibitors; Immune-related adverse events; Melanoma.

Publication types

Case Reports